• Chimeric Therapeutics has seen its stock jump, likely driven by the recent announcement that it secured A$1.62 million in funding.
  • This funding, an advance against its anticipated FY26 Research and Development Tax Incentive, provides crucial capital for Phase 1/2 clinical trial activities and general working capital.
  • The company also repaid and discharged a prior R&D funding facility, strengthening its liquidity and overall financial position.